13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2015-002820-20-NL (EUCTR) | 03/02/2016 | 21/01/2016 | Are alpha blockers effective in the treatment of bladder elimination problems in female patients with Multiple Sclerosis? | Are alpha blockers effective in the treatment of bladder elimination problems in female patients with Multiple Sclerosis? - Alpha blockers and Multiple Sclerosis (MS) | Bladder dysfunction in Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10069632;Term: Bladder dysfunction;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 20.1;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Silodyx | Erasmus MC Dept. Urology | NULL | Not Recruiting | Female: yes Male: no | 30 | Phase 3 | Netherlands |